Genomic marker predicts anti-PD-1 response in several cancers

Bookmark and Share
Published: 29 May 2015
Views: 1931
Dr Dung Le - Johns Hopkins Kimmel Cancer Center, Baltimore, USA

Dr Dung T. Le presents, at ASCO 2015, a phase II study that has identified the first genomic marker mismatch repair (MMR) deficiency to predict response to the anti-PD-1 antibody pembrolizumab.

Read the news article and watch the interview for more.